Fyarro Injection, Powder, Lyophilized, For Suspension
Product Images NDC 80803-153

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Fyarro (NDC 80803-153). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aadi Bioscience, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (Carton)

Label for FYARRO sirolimus protein-bound particles injection, powder, lyophilized for suspension, 100 mg per vial. The label indicates it is for intravenous infusion and single-dose vial with instructions to discard unused portion. The labeler is Aadi Bioscience, Inc.*

FDA Label Image

Image Of Proper Solution Flow Onto The Inside Wall Of The Vial (Figure1)

A black-and-white line drawing depicting a syringe inserted into the rubber stopper of a vial, possibly illustrating a step in the preparation of an intravenous suspension from a lyophilized powder vial.*

FDA Label Image

The Structural Formula Of Sirolimus (Structure)

Chemical structure of sirolimus, the active ingredient in FYARRO injection, powder, lyophilized, for suspension, 5 mg/mL by Aadi Bioscience, Inc. The structure shows the molecular arrangement of sirolimus with its characteristic rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.